Conjugated To A Detectable Label Or Radioisotope Or Radionuclide Or Heavy Metal-containing Compound Patents (Class 530/391.3)
-
Publication number: 20150017230Abstract: An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.Type: ApplicationFiled: March 1, 2013Publication date: January 15, 2015Applicant: ACADEMIA SINICAInventors: Han-Chung Wu, Mei-Ying Liao, Cheng-Wei Lin
-
Patent number: 8927225Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.Type: GrantFiled: September 8, 2009Date of Patent: January 6, 2015Assignee: The University of Hong KongInventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
-
Publication number: 20150004173Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Inventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Publication number: 20150004167Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: May 29, 2014Publication date: January 1, 2015Applicant: AbbVie Inc.Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
-
Publication number: 20150004162Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.Type: ApplicationFiled: December 21, 2012Publication date: January 1, 2015Inventors: Arun K. Kashyap, Ramesh R. Bhatt, Michael Horowitz, Lawrence Horowitz, Sihong Zhou, Ryann E. O'Neil, Charles H. Hannum, Aaron L. Kurtzman, Li Xu
-
Publication number: 20140377253Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.Type: ApplicationFiled: March 14, 2014Publication date: December 25, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
-
Publication number: 20140377174Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.Type: ApplicationFiled: January 4, 2013Publication date: December 25, 2014Inventors: Hendrik Jan Houthoff, Augustinus A.M.S. Van Dongen, Robbert Jan Kok, Dennis Christian Johannes Waalboer, Sytze Jan Buwalda, Niels Jurriaan Sijbrandi
-
Publication number: 20140377781Abstract: Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Inventor: Kenji YOSHIDA
-
Publication number: 20140378668Abstract: A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. This reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Carlos F. Barbas, III, Hitoshi Ban, Julia Gavrilyuk
-
Publication number: 20140377837Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.Type: ApplicationFiled: June 9, 2014Publication date: December 25, 2014Inventors: Brian AGNEW, Kyle Gee, Schuyler Corry
-
Publication number: 20140378831Abstract: The invention relates to a multifunctional nanomaterial comprising a nanorod comprising 1) a noble metal, wherein the nanorod exhibits surface plasmon resonance absorption in the near-infrared spectrum; 2) an up-conversion phosphor that absorbs infrared light and emits visible luminescence; and optionally 3) a biomolecule targeting moiety. The invention further relates to methods of detecting and treating cancer using the multifunctional nanomaterials of the invention.Type: ApplicationFiled: January 25, 2013Publication date: December 25, 2014Applicant: The Regents of the University of Colorado, a body corporateInventors: Wounjhang Park, Thomas Flaig, Xiaping Yang, Lih-Jen Shih Su, Kazunori Emoto
-
Patent number: 8916504Abstract: The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.Type: GrantFiled: September 30, 2009Date of Patent: December 23, 2014Assignee: Abbvie Inc.Inventors: Chung-Ming Hsieh, Yuliya A. Kutskova, John E. Memmott
-
Publication number: 20140370023Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: ApplicationFiled: May 27, 2014Publication date: December 18, 2014Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Publication number: 20140371431Abstract: A process for synthesizing and separating secretory IgA from a mixture of IgA monomer and IgA dimer is provided. The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is also provided. The process includes covalently binding affinity tagged or an epitope tagged recombinant secretory component to the IgM in the mixture and binding the affinity tagged or an epitope tagged secretory IgM to immobilized moieties on the solid phase support resin and then eluting the peptide tagged secretory IgM with a release buffer.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Stephen C. Brown, Michael R. Simon, Blaise Corthésy
-
Publication number: 20140369926Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: J. Andrew BRISTOL, Judith A. KANTOR
-
Publication number: 20140370016Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: July 31, 2014Publication date: December 18, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8911731Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.Type: GrantFiled: July 6, 2012Date of Patent: December 16, 2014Assignee: Janssen Pharmaceutica NVInventors: Marc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
-
Patent number: 8912311Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: April 16, 2013Date of Patent: December 16, 2014Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20140363873Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: May 8, 2014Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
-
Publication number: 20140363434Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: December 11, 2014Applicant: COMPLIX NVInventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
-
Patent number: 8906342Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: October 14, 2013Date of Patent: December 9, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Debbie Law, Kurt Gish
-
Patent number: 8907069Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: July 5, 2010Date of Patent: December 9, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
-
Patent number: 8906377Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: GrantFiled: December 15, 2010Date of Patent: December 9, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20140356364Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.Type: ApplicationFiled: August 15, 2012Publication date: December 4, 2014Applicant: AMPLIMMUNE, INC.Inventors: Solomon Langermann, Linda Liu, Shannon Marshall
-
Publication number: 20140356281Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 3, 2014Publication date: December 4, 2014Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
-
Patent number: 8900578Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: July 30, 2013Date of Patent: December 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Publication number: 20140349310Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.Type: ApplicationFiled: September 13, 2012Publication date: November 27, 2014Applicant: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu
-
Publication number: 20140348822Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: ApplicationFiled: June 10, 2014Publication date: November 27, 2014Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Publication number: 20140348745Abstract: The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.Type: ApplicationFiled: December 12, 2012Publication date: November 27, 2014Inventors: Roy H. Larsen, Jostein Dahle
-
Publication number: 20140348851Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.Type: ApplicationFiled: October 18, 2012Publication date: November 27, 2014Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITYInventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
-
Publication number: 20140348836Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: ApplicationFiled: September 5, 2012Publication date: November 27, 2014Applicant: Alligator Bioscience ABInventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
-
Publication number: 20140348785Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: November 7, 2012Publication date: November 27, 2014Inventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 8895007Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: December 7, 2011Date of Patent: November 25, 2014Assignee: Affitech Research ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Publication number: 20140341929Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: July 3, 2014Publication date: November 20, 2014Inventors: Ronald Vogels, Theodorus H.J. Kwaks
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140341809Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.Type: ApplicationFiled: May 16, 2014Publication date: November 20, 2014Applicants: University of Massachusetts, University of Notre DameInventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
-
Publication number: 20140341904Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140341905Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140342378Abstract: The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.Type: ApplicationFiled: May 22, 2014Publication date: November 20, 2014Applicant: STICHTING VOOR DE TECHNISCHE WETENSCHAPPENInventors: Waltherus Jacobus Wilhelmus VAN VENROOIJ, Gerardus Antonius SCHELLEKENS, Jozef Maria Hendrik RAATS, Rene Michael Antonius HOET
-
Patent number: 8889137Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: GrantFiled: October 1, 2010Date of Patent: November 18, 2014Assignees: Universität Duisberg Essen, Rheinische Friedrich Wilhelms —Universität BonnInventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer, Edelgard Schneweis
-
Publication number: 20140335096Abstract: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.Type: ApplicationFiled: November 27, 2012Publication date: November 13, 2014Inventors: David Edward Watson, Robert W. Siegel, Nan Jia, John Harrison Sloan
-
Publication number: 20140335016Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.Type: ApplicationFiled: November 28, 2012Publication date: November 13, 2014Applicant: NEUROPHAGE PHARMACEUTICALS, INC.Inventor: Rajaraman Krishnan
-
Publication number: 20140335107Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: March 19, 2014Publication date: November 13, 2014Applicant: GENENTECH, INC.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Publication number: 20140335014Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 8, 2014Publication date: November 13, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
-
Publication number: 20140335103Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: ApplicationFiled: April 3, 2014Publication date: November 13, 2014Applicant: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Publication number: 20140335538Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventor: Neil Cashman
-
Publication number: 20140336364Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Haruki OKAMURA, Tadao TANIMOTO, Kakuji TORIGOE, Toshi KUNIKATA, Mutsuko TANIGUCHI, Keizo KOHNO, Masashi KURIMOTO
-
Publication number: 20140328753Abstract: Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.Type: ApplicationFiled: November 15, 2012Publication date: November 6, 2014Applicants: UNIVERSITE BORDEAUX SEGALEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Gisele Clofent-Sanchez, Kamel Deramchia, Marie-Josee Joacobin, Stephane Bonetto, Jeanny Traineau
-
Publication number: 20140328851Abstract: Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy.Type: ApplicationFiled: May 15, 2014Publication date: November 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Gang Ren, Lei Zhang
-
Publication number: 20140328830Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.Type: ApplicationFiled: December 24, 2013Publication date: November 6, 2014Applicant: ONCOSYNERGY, INC.Inventor: W. Shawn Carbonell